Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008.[1] The second one was apixaban (Eliquis), approved in Europe in 2011[2] and in the United States in 2012.[3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015.[4] Betrixaban (Bevyxxa) was approved in the US in 2017.
